BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35126150)

  • 1. Deciphering the Effective Constituents and Mechanisms of
    He X; Hu Y; Liu W; Zhu G; Zhang R; You J; Shao Y; Li Y; Zhang Z; Cui J; He Y; Ge G; Yang H
    Front Pharmacol; 2021; 12():818227. PubMed ID: 35126150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic potential of traditional Chinese medicine in the prevention and treatment of digestive inflammatory cancer transformation: Portulaca oleracea L. as a promising drug.
    Shao G; Liu Y; Lu L; Wang L; Ji G; Xu H
    J Ethnopharmacol; 2024 Jun; 327():117999. PubMed ID: 38447616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinogen-like protein 2 aggravates nonalcoholic steatohepatitis via interaction with TLR4, eliciting inflammation in macrophages and inducing hepatic lipid metabolism disorder.
    Hu J; Wang H; Li X; Liu Y; Mi Y; Kong H; Xi D; Yan W; Luo X; Ning Q; Wang X
    Theranostics; 2020; 10(21):9702-9720. PubMed ID: 32863955
    [No Abstract]   [Full Text] [Related]  

  • 4. Resveratrol ameliorates hepatic steatosis and inflammation in methionine/choline-deficient diet-induced steatohepatitis through regulating autophagy.
    Ji G; Wang Y; Deng Y; Li X; Jiang Z
    Lipids Health Dis; 2015 Oct; 14():134. PubMed ID: 26498332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model.
    Tamura YO; Sugama J; Iwasaki S; Sasaki M; Yasuno H; Aoyama K; Watanabe M; Erion DM; Yashiro H
    J Pharmacol Exp Ther; 2021 Nov; 379(3):280-289. PubMed ID: 34535562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Yellow loosestrife (Lysimachia vulgaris var. davurica) ameliorates liver fibrosis in db/db mice with methionine- and choline-deficient diet-induced nonalcoholic steatohepatitis.
    Son YJ; Jung DS; Shin JM; Kim M; Yoo G; Nho CW
    BMC Complement Med Ther; 2021 Jan; 21(1):44. PubMed ID: 33494735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver-specific loss of Perilipin 2 alleviates diet-induced hepatic steatosis, inflammation, and fibrosis.
    Najt CP; Senthivinayagam S; Aljazi MB; Fader KA; Olenic SD; Brock JR; Lydic TA; Jones AD; Atshaves BP
    Am J Physiol Gastrointest Liver Physiol; 2016 May; 310(9):G726-38. PubMed ID: 26968211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice.
    Xu B; Jiang M; Chu Y; Wang W; Chen D; Li X; Zhang Z; Zhang D; Fan D; Nie Y; Shao F; Wu K; Liang J
    J Hepatol; 2018 Apr; 68(4):773-782. PubMed ID: 29273476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells.
    Chong LW; Hsu YC; Lee TF; Lin Y; Chiu YT; Yang KC; Wu JC; Huang YT
    BMC Gastroenterol; 2015 Feb; 15():22. PubMed ID: 25886887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of fatty acid synthase in nonalcoholic fatty liver disease.
    Dorn C; Riener MO; Kirovski G; Saugspier M; Steib K; Weiss TS; Gäbele E; Kristiansen G; Hartmann A; Hellerbrand C
    Int J Clin Exp Pathol; 2010 Mar; 3(5):505-14. PubMed ID: 20606731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyruvate dehydrogenase kinase 4 mediates lipogenesis and contributes to the pathogenesis of nonalcoholic steatohepatitis.
    Zhang M; Zhao Y; Li Z; Wang C
    Biochem Biophys Res Commun; 2018 Jan; 495(1):582-586. PubMed ID: 29128353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD44 is a key player in non-alcoholic steatohepatitis.
    Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
    J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatoprotective and antioxidant activities of extracts from Salvia-Nelumbinis naturalis against nonalcoholic steatohepatitis induced by methionine- and choline-deficient diet in mice.
    Liu Y; Song H; Wang L; Xu H; Shu X; Zhang L; Li Y; Li D; Ji G
    J Transl Med; 2014 Nov; 12():315. PubMed ID: 25406833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myricetin Modulates Macrophage Polarization and Mitigates Liver Inflammation and Fibrosis in a Murine Model of Nonalcoholic Steatohepatitis.
    Yao Q; Li S; Li X; Wang F; Tu C
    Front Med (Lausanne); 2020; 7():71. PubMed ID: 32195263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fat-laden macrophages modulate lobular inflammation in nonalcoholic steatohepatitis (NASH).
    Jindal A; Bruzzì S; Sutti S; Locatelli I; Bozzola C; Paternostro C; Parola M; Albano E
    Exp Mol Pathol; 2015 Aug; 99(1):155-62. PubMed ID: 26112094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease.
    Farrell GC; Haczeyni F; Chitturi S
    Adv Exp Med Biol; 2018; 1061():19-44. PubMed ID: 29956204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enoyl coenzyme A hydratase 1 alleviates nonalcoholic steatohepatitis in mice by suppressing hepatic ferroptosis.
    Liu B; Yi W; Mao X; Yang L; Rao C
    Am J Physiol Endocrinol Metab; 2021 May; 320(5):E925-E937. PubMed ID: 33813878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic vagus nerve regulates Kupffer cell activation via α7 nicotinic acetylcholine receptor in nonalcoholic steatohepatitis.
    Nishio T; Taura K; Iwaisako K; Koyama Y; Tanabe K; Yamamoto G; Okuda Y; Ikeno Y; Yoshino K; Kasai Y; Okuno M; Seo S; Sakurai T; Asagiri M; Hatano E; Uemoto S
    J Gastroenterol; 2017 Aug; 52(8):965-976. PubMed ID: 28044208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial gene polymorphisms alter hepatic cellular energy metabolism and aggravate diet-induced non-alcoholic steatohepatitis.
    Schröder T; Kucharczyk D; Bär F; Pagel R; Derer S; Jendrek ST; Sünderhauf A; Brethack AK; Hirose M; Möller S; Künstner A; Bischof J; Weyers I; Heeren J; Koczan D; Schmid SM; Divanovic S; Giles DA; Adamski J; Fellermann K; Lehnert H; Köhl J; Ibrahim S; Sina C
    Mol Metab; 2016 Apr; 5(4):283-295. PubMed ID: 27069868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceutical Efficacy of Gypenoside LXXV on Non-Alcoholic Steatohepatitis (NASH).
    Lee JH; Oh JY; Kim SH; Oh IJ; Lee YH; Lee KW; Lee WH; Kim JH
    Biomolecules; 2020 Oct; 10(10):. PubMed ID: 33050067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.